Nyxoah SA (NYXH) News
Follow Nyxoah SA (NYXH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Nyxoah Q3 Revenue Rises on US Commercialization
Belgium-based Nyxoah reported higher Q3 revenue, citing US commercialization.
EQUITY | Nov 05, 2026, 09:46 PM UTC
M
Nyxoah Lowers FY26 Revenue Guidance
Nyxoah shares are trading lower after the company lowered its FY26 revenue guidance.
EARNINGS | Oct 19, 2026, 02:48 PM UTC
M
Nyxoah Reports Preliminary Q3 2026 Results and Adjusts 2026 Revenue Guidance
Nyxoah announced preliminary third-quarter 2026 results and adjusted its revenue guidance for 2026; no figures were provided.
EQUITY | Oct 19, 2026, 12:05 PM UTC
L
Nyxoah Says Co Appoints Liam Kelly As Chief Executive Officer Effective October 1
Nyxoah SA EURONEXT:NYXH
NEWS | Sep 28, 2026, 08:35 PM UTC
L
Nyxoah SA (NYXH) Appoints Liam Kelly as CEO
Nyxoah SA appointed Liam Kelly as Chief Executive Officer, effective Oct 1, 2026, succeeding Olivier Taelman, to strengthen its U.S.-focused commercialization after FDA approval of Genio.Material DetailsContext by AI Ana
REGULATION | Sep 28, 2026, 08:32 PM UTC
L
Nyxoah Appoints Liam Kelly as Chief Executive Officer
REGULATED INFORMATIONINSIDE INFORMATIONNyxoah Appoints Liam Kelly as Chief Executive OfficerFurther strengthening the Company’s strategic U.S. presence and focusMont-Saint-Guibert, Belgium — September 28, 2026, 10:30 pm
NEWS | Sep 28, 2026, 08:32 PM UTC
L
Nyxoah Appoints Liam Kelly as CEO >NYXH.BT
Nyxoah Appoints Liam Kelly as CEO >NYXH.BT
NEWS | Sep 28, 2026, 08:30 PM UTC
H
Nyxoah Appoints Loic Moreau As Interim CFO, Effective Oct. 2, Succeeding John Landry; Reiterates FY26 Revenue Range Of €36M - €40M
Nyxoah SA (Euronext Brussels/NASDAQ: NYXH ) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today ann
LIVE | Sep 21, 2026, 08:02 PM UTC
L
Nyxoah implants first patient in U.S. BREATHE study for Genio
Nyxoah SA said the first patient has been implanted in BREATHE, its U.S. post-approval study of the Genio system. The multicenter, prospective single-arm study will enroll up to 229 adults and follow them up to five year
EQUITY | Sep 08, 2026, 08:00 AM UTC
L
Nyxoah announces first patient implanted in BREATHE post-approval study
Nyxoah said its first patient was implanted in BREATHE, the U.S. post-approval study of the Genio System.
EQUITY | Sep 07, 2026, 08:05 PM UTC
M
Nyxoah U.S. study meets primary safety and efficacy endpoints
Nyxoah said its U.S. obstructive sleep apnea (OSA) device met all primary safety and efficacy endpoints in patients with complete concentric collapse (CCC) of the soft palate. The company is preparing a premarket approva
EQUITY | Sep 02, 2026, 10:14 PM UTC
M
Nyxoah says U.S. Pivotal Study meets primary safety, efficacy endpoints
Nyxoah SA said its U.S. Pivotal Study met the primary safety and efficacy endpoints in complete concentric collapse patients.
EQUITY | Sep 02, 2026, 08:12 PM UTC
M
NYXH announces U.S. ACCCESS pivotal study meets safety, efficacy endpoints
NYXOAH said its ACCCESS U.S. pivotal study met primary safety and efficacy endpoints in complete concentric collapse patients.
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
NYXH - Information on the total number of voting rights and shares
NYXH - Information on the total number of voting rights and shares
EQUITY | Aug 25, 2026, 08:30 PM UTC
L
Nyxoah Lowers FY2026 Sales Guidance from $42.156M-$46.840M to $41.852M-$46.502M vs $44.410M Est
Nyxoah (NASDAQ: NYXH ) lowers FY2026 sales outlook from $42.156 million-$46.840 million to $41.852 million-$46.502 million vs $44.410 million estimate.
EARNINGS | Aug 05, 2026, 09:00 PM UTC
L
NYXH - Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
NYXH - Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
EQUITY | Aug 05, 2026, 08:05 PM UTC
H
Nyxoah Preliminary Q2 Revenue Rises From Q1; 2026 Outlook Reaffirmed
() -- Nyxoah SA (NYXH) said preliminary Q2 results showed global net revenue probably rose 21% to 7.7 million euros ($8.79 million) from Q1. US revenue rose 22% to 5.2 million euros, the company said Tuesday in a stateme
EARNINGS | Jul 07, 2026, 08:37 PM UTC
L
Nyxoah backs FY26 revenue view EUR 36M-EUR 40M
The company said, "The Company continues to expect global net revenue for the full year 2026 to be in the range of EUR 36 million to EUR 40 million."
EARNINGS | Jul 07, 2026, 08:13 PM UTC